MBX Biosciences, Inc. 8-K

What Happened

• MBX Biosciences (MBX) announced on June 12, 2026 (8-K, Regulation FD) one‑year results from its Phase 2 Avail™ trial and open‑label extension (OLE) for canvuparatide, an investigational once‑weekly PTH replacement therapy for chronic hypoparathyroidism (HP). At 12 weeks, 63% of canvuparatide patients (30/48) met the trial’s primary composite endpoint versus 31% for placebo (5/16; p=0.042). At one year, 57% of evaluable patients (31/54) were responders, with no contribution from rescue therapy in the final week.
• Pharmacokinetics supported once‑weekly dosing (Tmax 2–3 days; peak‑to‑trough ≈1.3 over a week). Key physiologic effects included maintained mean serum calcium in the normal range, reduced 24‑hour urine calcium, improved mean eGFR from baseline at Week 12 that persisted at one year, and bone‑turnover marker changes consistent with PTH replacement. Safety through one year was generally well tolerated: most adverse events were mild/moderate, no treatment‑related serious adverse events reported, and injection site reactions in 10% of OLE patients. MBX held a conference call/webcast on June 12, 2026 to discuss these data.

Key Details

• 12‑week primary endpoint: 63% (30/48) canvuparatide vs 31% (5/16) placebo (p=0.042).
• One‑year responder rate: 57% of evaluable patients (31/54); no PRN rescue contribution in last week.
• PK supports weekly dosing: Tmax 2–3 days; weekly peak‑to‑trough ratio ≈1.3.
• Safety: no treatment‑related serious adverse events; injection site reactions in 10% of OLE patients.

Why It Matters

• These results provide clinical evidence that canvuparatide may act as a physiologic PTH replacement with sustained control of serum calcium, reduced urinary calcium, signs of restored bone remodeling, and a safety profile acceptable through one year. For investors, the data support MBX’s development path toward a potential Phase 3 confirmatory trial and eventual regulatory discussions, but do not guarantee approval.
• MBX’s filing includes forward‑looking statements and reiterates risks (clinical, regulatory, manufacturing, financing and others) that could materially affect timelines and outcomes. Investors should view this as positive Phase 2/OLE data but remain mindful that additional trials and regulatory review are required.